| Outcome / Analysis | N | 0 months | 6 months | 0-6 month difference | |
|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | Mean (95%-CI) | P-value | ||
| Physician rating | |||||
| Main analysis: Patients with evaluable data at baseline | 44 | 7.20 (1.37) | 4.07 (2.48) | 3.14 (2.40-3.87) | < 0.001 |
| SA1: Patients with a disease duration of ≥ 12 months | 41 | 7.17 (1.41) | 4.22 (2.50) | 2.95 (2.20-3.70) | < 0.001 |
| SA2: Patients not using prophylactic antimigraine medications in months 0-6 | 30 | 7.33 (1.27) | 4.23 (2.45) | 3.10 (2.23-3.97) | < 0.001 |
| SA1 + SA2 | 27 | 7.30 (1.32) | 4.48 (2.44) | 2.82 (1.93-3.70) | < 0.001 |
| Patient rating | |||||
| Main analysis: Patients with evaluable data at baseline | 44 | 6.77 (1.79) | 3.93 (2.44) | 2.84 (2.05-3.64) | < 0.001 |
| SA1: Patients with a disease duration of ≥ 12 months | 41 | 6.71 (1.83) | 4.10 (2.43) | 2.61 (1.81-3.41) | < 0.001 |
| SA2: Patients not using prophylactic antimigraine medications in months 0-6 | 30 | 6.63 (1.52) | 3.53 (2.43) | 3.10 (2.12-4.08) | < 0.001 |
| SA1 + SA2 | 27 | 6.52 (1.55) | 3.74 (2.44) | 2.78 (1.77-3.79) | < 0.001 |